{"id":8929,"date":"2025-10-07T22:35:40","date_gmt":"2025-10-07T22:35:40","guid":{"rendered":"https:\/\/zamra.co.zm\/vs\/new2025\/?post_type=ova_sev&#038;p=8929"},"modified":"2026-06-25T14:14:23","modified_gmt":"2026-06-25T14:14:23","slug":"monitoring-the-safety-of-medicines","status":"publish","type":"ova_sev","link":"https:\/\/zamra.co.zm\/vs\/new2025\/services\/monitoring-the-safety-of-medicines\/","title":{"rendered":"Monitoring the Safety of Medicines"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"8929\" class=\"elementor elementor-8929\">\n\t\t\t\t<div class=\"elementor-element elementor-element-46fc45b e-flex e-con-boxed e-con e-parent\" data-id=\"46fc45b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f031e7e elementor-widget elementor-widget-text-editor\" data-id=\"f031e7e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"896\" data-end=\"1275\">The Monitoring the Safety of Medicines programme is responsible for the continuous assessment and monitoring of the safety of medicines after they have been authorized for use. Through pharmacovigilance activities, ZAMRA collects, evaluates, and responds to reports of adverse drug reactions, medication errors, product quality issues, and other medicine-related safety concerns.<\/p><p data-start=\"1277\" data-end=\"1644\">The programme works closely with healthcare professionals, pharmaceutical companies, patients, and international regulatory partners to identify potential risks associated with medicines and implement appropriate risk management measures. These activities help ensure that the benefits of medicines continue to outweigh any potential risks throughout their lifecycle.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>The Monitoring the Safety of Medicines programme is responsible for the continuous assessment and monitoring of the safety of medicines after they have been authorized for use. Through pharmacovigilance activities, ZAMRA collects, evaluates, and responds to reports of adverse drug reactions, medication errors, product quality issues, and other medicine-related safety concerns. The programme works closely [&hellip;]<\/p>\n","protected":false},"featured_media":8961,"comment_status":"open","ping_status":"closed","template":"","cat_sev":[26],"class_list":["post-8929","ova_sev","type-ova_sev","status-publish","has-post-thumbnail","hentry","cat_sev-regulations"],"_links":{"self":[{"href":"https:\/\/zamra.co.zm\/vs\/new2025\/wp-json\/wp\/v2\/ova_sev\/8929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zamra.co.zm\/vs\/new2025\/wp-json\/wp\/v2\/ova_sev"}],"about":[{"href":"https:\/\/zamra.co.zm\/vs\/new2025\/wp-json\/wp\/v2\/types\/ova_sev"}],"replies":[{"embeddable":true,"href":"https:\/\/zamra.co.zm\/vs\/new2025\/wp-json\/wp\/v2\/comments?post=8929"}],"version-history":[{"count":5,"href":"https:\/\/zamra.co.zm\/vs\/new2025\/wp-json\/wp\/v2\/ova_sev\/8929\/revisions"}],"predecessor-version":[{"id":10023,"href":"https:\/\/zamra.co.zm\/vs\/new2025\/wp-json\/wp\/v2\/ova_sev\/8929\/revisions\/10023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zamra.co.zm\/vs\/new2025\/wp-json\/wp\/v2\/media\/8961"}],"wp:attachment":[{"href":"https:\/\/zamra.co.zm\/vs\/new2025\/wp-json\/wp\/v2\/media?parent=8929"}],"wp:term":[{"taxonomy":"cat_sev","embeddable":true,"href":"https:\/\/zamra.co.zm\/vs\/new2025\/wp-json\/wp\/v2\/cat_sev?post=8929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}